While most companies are starting in the less risky territory of validated targets for liver diseases, where drug delivery is easy and therapeutic effects have been demonstrated in clinical trials, Modalis is one of the few promising companies tackling CNS diseases (central nerve system disease), where therapeutic drug development in other modalities is difficult and unmet medical need is high. Modalis was featured in the following (paid) article.

2025. 3. 21. BioCentury “BioCentury – Solving CNS delivery will open big doors for epigenome editing: a Perspective“